<DOC>
	<DOCNO>NCT00004810</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess safety efficacy 4-aminosalicylic acid patient mildly moderately severe ulcerative colitis .</brief_summary>
	<brief_title>Phase II Placebo-Controlled Study 4-Aminosalicylic Acid Ulcerative Colitis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize study . Patients stratify extent disease . Patients randomly assign oral 4-aminosalicylic acid ( 4-ASA ) placebo administer daily 6 week . Optional 4-ASA available patient 1 year . Concurrent therapy low-dose sulfasalazine , prednisone , equivalent allow .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Aminosalicylic Acid</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Mildly moderately severe ulcerative colitis Patient age : 18 80</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>gastrointestinal disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>ulcerative colitis</keyword>
</DOC>